Zai Lab ZLAB Stock
Zai Lab Price Chart
Zai Lab ZLAB Financial and Trading Overview
| Zai Lab stock price | 24.6 USD |
| Previous Close | 26.04 USD |
| Open | 25.75 USD |
| Bid | 13.12 USD x 200 |
| Ask | 23.88 USD x 200 |
| Day's Range | 23.43 - 25.94 USD |
| 52 Week Range | 15.96 - 29.02 USD |
| Volume | 1.22M USD |
| Avg. Volume | 1.03M USD |
| Market Cap | 3.07B USD |
| Beta (5Y Monthly) | 0.721 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.13 USD |
ZLAB Valuation Measures
| Enterprise Value | 2.47B USD |
| Trailing P/E | N/A |
| Forward P/E | -12.406823 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.9525843 |
| Price/Book (mrq) | 4.9101796 |
| Enterprise Value/Revenue | 5.601 |
| Enterprise Value/EBITDA | -9.449 |
Trading Information
Zai Lab Stock Price History
| Beta (5Y Monthly) | 0.721 |
| 52-Week Change | 19.72% |
| S&P500 52-Week Change | 12.28% |
| 52 Week High | 29.02 USD |
| 52 Week Low | 15.96 USD |
| 50-Day Moving Average | 24.66 USD |
| 200-Day Moving Average | 21.26 USD |
ZLAB Share Statistics
| Avg. Volume (3 month) | 1.03M USD |
| Avg. Daily Volume (10-Days) | 1.29M USD |
| Shares Outstanding | 124.84M |
| Float | 97.29M |
| Short Ratio | 8.01 |
| % Held by Insiders | 1.91% |
| % Held by Institutions | 33.36% |
| Shares Short | 8.09M |
| Short % of Float | 6.63% |
| Short % of Shares Outstanding | 6.51% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -44.91% |
| Operating Margin (ttm) | -62.99% |
| Gross Margin | 0.63% |
| EBITDA Margin | -59.27% |
Management Effectiveness
| Return on Assets (ttm) | -15.93% |
| Return on Equity (ttm) | -29.98% |
Income Statement
| Revenue (ttm) | 441.73M USD |
| Revenue Per Share (ttm) | 3.96 USD |
| Quarterly Revenue Growth (yoy) | -6.80% |
| Gross Profit (ttm) | 2.79M USD |
| EBITDA | -261814000 USD |
| Net Income Avi to Common (ttm) | -198386000 USD |
| Diluted EPS (ttm) | -1.8 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 559.66M USD |
| Total Cash Per Share (mrq) | 4.98 USD |
| Total Debt (mrq) | 267.45M USD |
| Total Debt/Equity (mrq) | 47.48 USD |
| Current Ratio (mrq) | 2.037 |
| Book Value Per Share (mrq) | 5.01 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -159208000 USD |
| Levered Free Cash Flow (ttm) | -120174496 USD |
Profile of Zai Lab
| Country | United States |
| State | N/A |
| City | Pudong |
| Address | Building B |
| ZIP | 201203 |
| Phone | 86 21 6163 2588 |
| Website | https://www.zailaboratory.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1784 |
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Q&A For Zai Lab Stock
What is a current ZLAB stock price?
Zai Lab ZLAB stock price today per share is 24.6 USD.
How to purchase Zai Lab stock?
You can buy ZLAB shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zai Lab?
The stock symbol or ticker of Zai Lab is ZLAB.
Which industry does the Zai Lab company belong to?
The Zai Lab industry is Biotechnology.
How many shares does Zai Lab have in circulation?
The max supply of Zai Lab shares is 124.84M.
What is Zai Lab Price to Earnings Ratio (PE Ratio)?
Zai Lab PE Ratio is now.
What was Zai Lab earnings per share over the trailing 12 months (TTM)?
Zai Lab EPS is -1.8 USD over the trailing 12 months.
Which sector does the Zai Lab company belong to?
The Zai Lab sector is Healthcare.
Zai Lab ZLAB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25136.27 USD — |
-0.91
|
7.74B USD — | 24872.41 USD — | 25423.09 USD — | — - | 7.74B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Golden Dragon China
HXC
US
|
5522.55 USD — |
+0.84
|
— — | 5440.67 USD — | 5523.79 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
1937.83 USD — |
-1.05
|
— — | 1915.46 USD — | 1955.74 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7211.27 USD — |
-0.5
|
— — | 7149.19 USD — | 7238.9 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1368.29 USD — |
-0.34
|
— — | 1358.68 USD — | 1373.65 USD — | — - | — — |
